Thomas Kuhn is the founder of Poxel. Latest round: Series A. Backed by Edmond de Rothschild Investment Partners, InnoBio fund, Crédit Agricole Private Equity.
Thomas Kuhn is the co-founder and CEO of Poxel, a clinical-stage biopharmaceutical company focused on developing treatments for metabolic diseases. He previously led diabetes clinical development at Merck and guided Poxel through its Series A funding and public listing on Euronext Paris.
Full founder directory · Investor directory · Company funding database · Fundraising library